Trial Coordinator: Kathryn Monson
Lead Researcher: Sue Catt
PrefHer was an industry-funded, multi-centre study, examining patient preference between two methods of administering an important breast cancer drug. This crossover study was conducted across 12 countries using pre- and post-treatment questionnaires to determine which method of administration patients prefer. The study evaluated the experiences and satisfaction of health care professionals with the two methods, and explored the factors influencing patient preference.
Gligorov J, Curigliano G, Müller V, Knoop A, Jenkins V, Verma S, Osborne S, Lauer S, Machackova Z, Fallowfield L, Pivot X. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. The Breast, 2017: 34:89–95. Article first published online 23 May 2017. Print version expected August 2017.
Fallowfield L, Osborne S, Langridge C, Monson K, Kilkerr J, Jenkins V. Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study. The Breast, Article first published online 23 January 2015.
Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L on behalf of the PrefHer Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Annals of Oncology 25:1979-1987
Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield LJ for the PrefHer Study Group Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. The Lancet Oncology 14(10): 962-70, 2013 doi:10.1016/S1470-2045(13)70383-8
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study Presented at the European Society for Medical Oncology 2016 (ESMO) Congress, 7–11th October 2016 in Copenhagen.
Patient preference for subcutaneous versus intravenous adjuvant trastuzumab: Results of the PrefHer Study. Presented at the 13th St. Gallen International Breast Cance Conference, 13-16th March 2013.
Reasons for patients' preferences for subcutanous or intravenous trastuzumab in the PrefHer study. Presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO), 27th September - 1st October 2013.